{"id":849047,"date":"2025-05-08T08:34:14","date_gmt":"2025-05-08T12:34:14","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/adial-pharmaceuticals-granted-end-of-phase-2-meeting-from-the-u-s-food-and-drug-administration\/"},"modified":"2025-05-08T08:34:14","modified_gmt":"2025-05-08T12:34:14","slug":"adial-pharmaceuticals-granted-end-of-phase-2-meeting-from-the-u-s-food-and-drug-administration","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/adial-pharmaceuticals-granted-end-of-phase-2-meeting-from-the-u-s-food-and-drug-administration\/","title":{"rendered":"Adial Pharmaceuticals Granted End of Phase 2 Meeting from the\u00a0U.S. Food and Drug Administration"},"content":{"rendered":"
\n

\n Meeting to Take Place on July 25, 2025<\/em>\n <\/p>\n

\n Meeting\u2019s Purpose is To Discuss Upcoming Clinical Development Plan and Protocol Designs<\/em>\n <\/p>\n

GLEN ALLEN, Va., May 08, 2025 (GLOBE NEWSWIRE) — Adial Pharmaceuticals, Inc. (NASDAQ: ADIL<\/strong>) (\u201cAdial\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that the FDA has granted Adial\u2019s request for an End of Phase 2 meeting to discuss Adial\u2019s proposed clinical development plan and seek FDA guidance on the Phase 3 adaptive with enrichment design of the upcoming clinical trial for AD04. The meeting will take place on July 25, 2025. AD04 is the Company\u2019s lead investigational genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients (defined as < 8 drinks\/drinking day).<\/p>\n

Cary Claiborne, President and Chief Executive Officer of Adial, commented, \u201cWe recently announced the successful results of our Type D Meeting with FDA confirming Adial\u2019s 505(b)(2) regulatory bridging strategy. Concurrently, we have made strong progress in developing the design of our Phase 3 trial and look forward to aligning with the FDA on key requirements to move AD04 forward. Our recent analyses have reinforced the selection of our target patient population and continue to support AD04\u2019s potential to effectively treat AUD and related conditions. We remain confident in the path ahead and look forward to sharing a comprehensive update following our FDA meeting in July.\u201d<\/p>\n

\n About Adial Pharmaceuticals, Inc.<\/strong>\n <\/p>\n

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions and related disorders. The Company\u2019s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company\u2019s ONWARD\u2122 pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes identified using the Company\u2019s companion diagnostic genetic test. ONWARD showed promising results in reducing drinking in heavy drinking patients, and no overt safety or tolerability concerns. AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. Additional information is available at www.adial.com<\/a>.\u00a0<\/p>\n

\n Forward-Looking Statements<\/strong>\n <\/p>\n

This communication contains certain \u201cforward-looking statements\u201d within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words \u201cbelieves,\u201d \u201cexpects,\u201d \u201canticipates,\u201d \u201cintends,\u201d \u201cprojects,\u201d \u201cestimates,\u201d \u201cplans\u201d and similar expressions or future or conditional verbs such as \u201cwill,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201cmay\u201d and \u201ccould\u201d are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. The forward-looking statements include statements regarding aligning with the FDA on key requirements to move AD04 forward, AD04\u2019s potential to effectively treat AUD and related conditions, sharing a comprehensive update following the FDA meeting in July and the potential of AD04 to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. Any forward-looking statements included herein reflect our current views, and they involve certain risks and uncertainties, including, among others, our ability to obtain feedback on the overall design of our Phase 3 program from the FDA , our ability to pursue our regulatory strategy, our ability to advance ongoing partnering discussions, our ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, our ability to develop strategic partnership opportunities and maintain collaborations, our ability to obtain or maintain the capital or grants necessary to fund our research and development activities, our ability to complete clinical trials on time and achieve desired results and benefits as expected, regulatory limitations relating to our ability to promote or commercialize our product candidates for specific indications, acceptance of our product candidates in the marketplace and the successful development, marketing or sale of our products, our ability to maintain our license agreements, the continued maintenance and growth of our patent estate and our ability to retain our key employees or maintain our Nasdaq listing. These risks should not be construed as exhaustive and should be read together with the other cautionary statement included in our Annual Report on Form 10-K for the year ended December 31, 2024, subsequent Quarterly Reports on Form 10-Q and current reports on Form 8-K filed with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was initially made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law.<\/p>\n

\n Contact:<\/strong>\n <\/p>\n

Crescendo Communications, LLC<\/p>\n

David Waldman \/ Alexandra Schilt<\/p>\n

Tel: 212-671-1020<\/p>\n

Email: adil@crescendo-ir.com<\/a>\u00a0<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Meeting to Take Place on July 25, 2025 Meeting\u2019s Purpose is To Discuss Upcoming Clinical Development Plan and Protocol Designs GLEN ALLEN, Va., May 08, 2025 (GLOBE NEWSWIRE) — Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (\u201cAdial\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that the FDA has granted Adial\u2019s request for an End of Phase 2 meeting to discuss Adial\u2019s proposed clinical development plan and seek FDA guidance on the Phase 3 adaptive with enrichment design of the upcoming clinical trial for AD04. The meeting will take place on July 25, 2025. AD04 is the Company\u2019s lead investigational genetically targeted, serotonin-3 receptor antagonist, therapeutic agent … <\/p>\n

Continue reading “Adial Pharmaceuticals Granted End of Phase 2 Meeting from the\u00a0U.S. Food and Drug Administration”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-849047","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAdial Pharmaceuticals Granted End of Phase 2 Meeting from the\u00a0U.S. Food and Drug Administration - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/adial-pharmaceuticals-granted-end-of-phase-2-meeting-from-the-u-s-food-and-drug-administration\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Adial Pharmaceuticals Granted End of Phase 2 Meeting from the\u00a0U.S. Food and Drug Administration - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Meeting to Take Place on July 25, 2025 Meeting\u2019s Purpose is To Discuss Upcoming Clinical Development Plan and Protocol Designs GLEN ALLEN, Va., May 08, 2025 (GLOBE NEWSWIRE) — Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (\u201cAdial\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that the FDA has granted Adial\u2019s request for an End of Phase 2 meeting to discuss Adial\u2019s proposed clinical development plan and seek FDA guidance on the Phase 3 adaptive with enrichment design of the upcoming clinical trial for AD04. The meeting will take place on July 25, 2025. AD04 is the Company\u2019s lead investigational genetically targeted, serotonin-3 receptor antagonist, therapeutic agent … Continue reading "Adial Pharmaceuticals Granted End of Phase 2 Meeting from the\u00a0U.S. Food and Drug Administration"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/adial-pharmaceuticals-granted-end-of-phase-2-meeting-from-the-u-s-food-and-drug-administration\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-08T12:34:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0NjUwOCM2OTI2OTkxIzIwMTgzMDI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adial-pharmaceuticals-granted-end-of-phase-2-meeting-from-the-u-s-food-and-drug-administration\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adial-pharmaceuticals-granted-end-of-phase-2-meeting-from-the-u-s-food-and-drug-administration\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Adial Pharmaceuticals Granted End of Phase 2 Meeting from the\u00a0U.S. Food and Drug Administration\",\"datePublished\":\"2025-05-08T12:34:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adial-pharmaceuticals-granted-end-of-phase-2-meeting-from-the-u-s-food-and-drug-administration\\\/\"},\"wordCount\":846,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adial-pharmaceuticals-granted-end-of-phase-2-meeting-from-the-u-s-food-and-drug-administration\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ0NjUwOCM2OTI2OTkxIzIwMTgzMDI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adial-pharmaceuticals-granted-end-of-phase-2-meeting-from-the-u-s-food-and-drug-administration\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adial-pharmaceuticals-granted-end-of-phase-2-meeting-from-the-u-s-food-and-drug-administration\\\/\",\"name\":\"Adial Pharmaceuticals Granted End of Phase 2 Meeting from the\u00a0U.S. Food and Drug Administration - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adial-pharmaceuticals-granted-end-of-phase-2-meeting-from-the-u-s-food-and-drug-administration\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adial-pharmaceuticals-granted-end-of-phase-2-meeting-from-the-u-s-food-and-drug-administration\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ0NjUwOCM2OTI2OTkxIzIwMTgzMDI=\",\"datePublished\":\"2025-05-08T12:34:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adial-pharmaceuticals-granted-end-of-phase-2-meeting-from-the-u-s-food-and-drug-administration\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adial-pharmaceuticals-granted-end-of-phase-2-meeting-from-the-u-s-food-and-drug-administration\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adial-pharmaceuticals-granted-end-of-phase-2-meeting-from-the-u-s-food-and-drug-administration\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ0NjUwOCM2OTI2OTkxIzIwMTgzMDI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ0NjUwOCM2OTI2OTkxIzIwMTgzMDI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adial-pharmaceuticals-granted-end-of-phase-2-meeting-from-the-u-s-food-and-drug-administration\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Adial Pharmaceuticals Granted End of Phase 2 Meeting from the\u00a0U.S. Food and Drug Administration\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Adial Pharmaceuticals Granted End of Phase 2 Meeting from the\u00a0U.S. Food and Drug Administration - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/adial-pharmaceuticals-granted-end-of-phase-2-meeting-from-the-u-s-food-and-drug-administration\/","og_locale":"en_US","og_type":"article","og_title":"Adial Pharmaceuticals Granted End of Phase 2 Meeting from the\u00a0U.S. Food and Drug Administration - Market Newsdesk","og_description":"Meeting to Take Place on July 25, 2025 Meeting\u2019s Purpose is To Discuss Upcoming Clinical Development Plan and Protocol Designs GLEN ALLEN, Va., May 08, 2025 (GLOBE NEWSWIRE) — Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (\u201cAdial\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that the FDA has granted Adial\u2019s request for an End of Phase 2 meeting to discuss Adial\u2019s proposed clinical development plan and seek FDA guidance on the Phase 3 adaptive with enrichment design of the upcoming clinical trial for AD04. The meeting will take place on July 25, 2025. AD04 is the Company\u2019s lead investigational genetically targeted, serotonin-3 receptor antagonist, therapeutic agent … Continue reading \"Adial Pharmaceuticals Granted End of Phase 2 Meeting from the\u00a0U.S. Food and Drug Administration\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/adial-pharmaceuticals-granted-end-of-phase-2-meeting-from-the-u-s-food-and-drug-administration\/","og_site_name":"Market Newsdesk","article_published_time":"2025-05-08T12:34:14+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0NjUwOCM2OTI2OTkxIzIwMTgzMDI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adial-pharmaceuticals-granted-end-of-phase-2-meeting-from-the-u-s-food-and-drug-administration\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adial-pharmaceuticals-granted-end-of-phase-2-meeting-from-the-u-s-food-and-drug-administration\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Adial Pharmaceuticals Granted End of Phase 2 Meeting from the\u00a0U.S. Food and Drug Administration","datePublished":"2025-05-08T12:34:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adial-pharmaceuticals-granted-end-of-phase-2-meeting-from-the-u-s-food-and-drug-administration\/"},"wordCount":846,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adial-pharmaceuticals-granted-end-of-phase-2-meeting-from-the-u-s-food-and-drug-administration\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0NjUwOCM2OTI2OTkxIzIwMTgzMDI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adial-pharmaceuticals-granted-end-of-phase-2-meeting-from-the-u-s-food-and-drug-administration\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/adial-pharmaceuticals-granted-end-of-phase-2-meeting-from-the-u-s-food-and-drug-administration\/","name":"Adial Pharmaceuticals Granted End of Phase 2 Meeting from the\u00a0U.S. Food and Drug Administration - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adial-pharmaceuticals-granted-end-of-phase-2-meeting-from-the-u-s-food-and-drug-administration\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adial-pharmaceuticals-granted-end-of-phase-2-meeting-from-the-u-s-food-and-drug-administration\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0NjUwOCM2OTI2OTkxIzIwMTgzMDI=","datePublished":"2025-05-08T12:34:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adial-pharmaceuticals-granted-end-of-phase-2-meeting-from-the-u-s-food-and-drug-administration\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/adial-pharmaceuticals-granted-end-of-phase-2-meeting-from-the-u-s-food-and-drug-administration\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adial-pharmaceuticals-granted-end-of-phase-2-meeting-from-the-u-s-food-and-drug-administration\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0NjUwOCM2OTI2OTkxIzIwMTgzMDI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0NjUwOCM2OTI2OTkxIzIwMTgzMDI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adial-pharmaceuticals-granted-end-of-phase-2-meeting-from-the-u-s-food-and-drug-administration\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Adial Pharmaceuticals Granted End of Phase 2 Meeting from the\u00a0U.S. Food and Drug Administration"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/849047","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=849047"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/849047\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=849047"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=849047"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=849047"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}